This study was designed to investigate the relationship between serum p53, tissue p53 and tissue permeability glycoprotein (P-gp) levels in gastric cancer. Serum levels of p53 were detected by enzyme-linked immunosorbent assay, and tissue p53 and P-gp levels were analysed by immunohistochemistry. In total, 63.0% of gastric cancer tissue samples tested positive for P-gp and 58.7% of samples tested positive for p53. Tissue P-gp immunoreactivity was significantly correlated with tissue p53 immunoreactivity, and both tissue p53 and P-gp immunoreactivity were significantly correlated to the degree of cancer cell differentiation. The percentage of gastric cancer patients with serum positive for p53 was 36.2%, which was significantly higher than the rate in non-cancerous gastric disease patients. Serum p53 was significantly correlated to tissue p53 and tissue P-gp, inferring that the presence of p53 in the serum could indicate the status of tissue p53 and P-gp. This could, therefore, be useful for screening for the most appropriate (lowest toxicity and highest effectiveness) drugs to use ahead of (neo)-adjuvant chemotherapy.
ParkinDM: Epidemiology of cancer global patterns and trends. Toxicol Lett1998; 102–103: 227–234.
3.
XuGW: Present status and problems in the treatment of gastric cancer. J Surg Concepts Practice2003; 8: 3–6 [in Chinese].
4.
YehKHChengAL: Recent advances in therapy for gastric cancer. J Formos Med Assoc2004; 103: 171–185.
5.
PozzoCBaroneCSzantoJ: Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: Results of a randomized phase II study. Ann Oncol2004; 15: 1773–1781.
6.
KamoshidaSSuzukiMShimomuraR: Immunostaining of thymidylate synthase and p53 for predicting chemoresistance to S-1/cisplatin in gastric cancer. Br J Cancer2007; 96: 277–283.
7.
CatalanoVBaldelliAMGiordaniP: Molecular markers predictive of response to chemotherapy in gastrointestinal tumours. Crit Rev Oncol Hematol2001; 38: 93–104.
8.
YonemuraYKinoshitaKFujimuraT: Correlation of the histological effects and survival after neoadjuvant chemotherapy on gastric cancer patients. Hepatogastroenterology1996; 43: 1260–1272.
9.
HamadaMFujiwaraTHizutaA: The p53 gene is a potent determinant of chemo-sensitivity and radiosensitivity in gastric and colorectal cancers. J Cancer Res Clin Oncol1996; 122: 360–365.
10.
CascinuSGrazianoFFerroED: Expression of p53 protein and resistance to preoperative chemotherapy in locally advanced gastric carcinoma. Cancer1998; 83: 1917–1922.
11.
NakataBChungKHOgawaM: p53 protein overexpression as a predictor of the response to chemotherapy in gastric cancer. Surg Today1998; 28: 595–598.
12.
LenzHJLeichmanCGDanenbergKD: Thymidylate synthase mRNA level in adenocarcinoma of the stomach: A predictor for primary tumor response and overall survival. J Clin Oncol1996; 14: 176–182.
13.
YehKHShunCTChenCL: High expression of thymidylate synthase is associated with the drug resistance of gastric carcinoma to high dose 5-fluorouracil-based systemic chemotherapy. Cancer1998; 82: 1626–1631.
14.
MetzgerRLeichmanCGDanenbergKD: ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol1998; 16: 309–316.
15.
JoshiAAWangQStuttleDP: p53 modulation of DNA topoisomerase II gene expression. Cell Biochem Biophys2000; 33: 209–216.
16.
QuelleFWWangLFengJ: Cytokine rescue of p53-dependent apoptosis and cell cycle arrest is mediated by distinct Jak kinase signaling pathways. Genes Dev1998; 12: 1099–1107.
17.
DeveciMSDeveciG: Prognostic value of p53 protein and MK-1 (a tumor-associated antigen) expression in gastric carcinoma. Gastric Cancer2007; 10: 112–116.
18.
VernhetLCourtoisAAllainN: Overexpression of the multidrug resistance-associated protein (MRP1) in human heavy metal-selected tumor cells. FEBS Lett1999; 443: 321–325.
19.
MaliepaardMvan GastelenMAde JongLA: Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer Res1999; 59: 4559–4563.
20.
ChoiCHSunKHAnCS: Reversal of P-glycoprotein-mediated multidrug resistance by 5,6,7,3′,4′-pentamethoxyflavone (Sinensetin). Biochem Biophys Res Commun2002; 295: 832–840.
21.
LeeTBParkJHMinYD: Epigenetic mechanisms involved in differential MDR1 mRNA expression between gastric and colon cancer cell lines and rationales for clinical chemotherapy. BMC Gastroenterol2008; 8: 33.
22.
XieXYTanYJZhuYL: Relation between mutant p53 and multidrug resistance in gastric cancer. Zhejiang Da Xue Xue Bao Yi Xue Ban2006; 35: 91–98 [in Chinese].
23.
HamiltonSRAaltonenLA (eds): World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of the Digestive System. Lyon; IARC Press, 2000; pp 39–52.
24.
BokuNOhtsuAYoshidaS: Significance of biological markers for predicting prognosis and selecting chemotherapy regimens of advanced gastric cancer patients between continuous infusion of 5-FU and a combination of 5-FU and cisplatin. Jpn J Clin Oncol2007; 37: 275–281.
25.
ShiHLuDShuY: Expression of multidrug resistance-related proteins p-glycoproteinglutathione-S-transferases, topoisomerase-II and lung resistance protein in primary gastric cardiac adenocarcinoma. Cancer Invest2008; 26: 344–351.
26.
OhSYKwonHCKimSH: Clinicopathologic significance of HIF-1α, p53, and VEGF expression and preoperative serum VEGF level in gastric cancer. BMC Cancer2008; 8: 123.
27.
AttallahAMAbdel-AzizMMEl-SayedAM: Detection of serum p53 protein in patients with different gastrointestinal cancers. Cancer Detect Prev2003; 27: 127–131.
28.
Brandt-RaufPWChenJMMarionMJ: Conformational effects in the p53 protein of mutations induced during chemical carcinogenesis: Molecular dynamic and immunologic analysis. J Protein Chem1996; 15: 367–375.
29.
FontaniniGFioreLBiginiD: Levels of p53 antigen in the serum of non-small cell lung cancer patients correlate with positive p53 immunohistochemistry on tumor sections. Int J Oncol1994; 54: 4855–4858.
30.
VojtesekBFisherCJBarnesDM: Comparison between p53 staining in tissue sections and p53 proteins levels measured by an ELISA technique. Br J Cancer1993; 67: 1254–1258.
